Published online before print April 15, 2004, doi: 10.1161/01.STR.0000126827.69286.90
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1316.)
© 2004 American Heart Association, Inc.
Original Contributions |
Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage
Relationship to Clinical and Radiological Outcome
From Neurovascular Research Laboratory and the Stroke Unit (J.A.-S., P.D., S.A., C.A.M., J.A., M.R., E.S., M.Q., J. Montaner) and Vascular Biology and Hemostasis Laboratory (J. Monasterio), Hospital Universitario Vall d’Hebron, Barcelona, Spain.
Correspondence to Dr José Álvarez-Sabín, Unitat Neurovascular (Servei de Neurologia) 9 Planta, Hospital Universitario Vall d’Hebron, Passeig Vall d’Hebrón 119-129, 08035 Barcelona, Spain. E-mail josalvar{at}vhebron.net
Background and Purpose— Matrix metalloproteinases (MMPs) are related to blood–brain barrier disruption, and some members of this family have been recently involved in brain bleedings. We aimed to investigate the temporal profile of MMPs and their natural inhibitors (TIMPs) after acute intracerebral hemorrhage (ICH) and to study its influence on neuroimaging and clinical outcome.
Methods— MMP-2, MMP-9, and MMP-3, as well as TIMP-1 and TIMP-2, were serially determined by enzyme-linked immunosorbent assay on admission (<12 hours), and at 24 hours, 48 hours, 7 days, and 3 months in 21 ICH patients. ICH and perihematomal edema (PE) volumes were serially measured on baseline and follow-up computed tomography (48 hours, 7 days, and 3 months), just at the time of neurological assessment.
Results— Deep ICH was found in 62% patients. Baseline ICH volume did not influence MMP-TIMP level. Highest levels of MMP-2 and TIMP-2 were found at baseline, for MMP-9 and TIMP-1 at 24 hours, and for MMP-3 at 24 to 48 hours. Baseline MMP-9 was positively correlated to PE volume (r=0.67, P=0.004) and, conversely, its inhibitor TIMP-1 was negatively correlated to PE (r=–0.51, P=0.04). Mortality reached 35% and MMP-3 was the only MMP/TIMP related to mortality (7.5 versus 2.4 ng/mL; P=0.035) and its most powerful baseline predictor (odds ratio = 22, confidence interval: 1.5 to 314.2). Both MMP-9 and MMP-3 correlated to the residual scar volume at 3 months (r=0.68, P=0.01 for baseline MMP-9, and r=0.86, P<0.001 for 24-hour MMP-3).
Conclusions— A characteristic temporal profile of MMP/TIMP release exists in ICH. Increased MMP-9 is associated with PE, and increased MMP-3 is associated with mortality. Both molecules are related to residual cavity volume.
Key Words: brain edema • intracerebral hemorrhage • metalloproteinases • stroke
This article has been cited by other articles:
 |
|
 |
|
  M. Xue, M. D. Hollenberg, A. Demchuk, and V. W. Yong Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice Stroke, June 1, 2009; 40(6): 2199 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xue, Y. Fan, S. Liu, D. A. Zygun, A. Demchuk, and V. W. Yong Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage Brain, January 1, 2009; 132(1): 26 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, October 16, 2007; 116(16): e391 - e413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, June 1, 2007; 38(6): 2001 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Krizanac-Bengez, M. Hossain, V. Fazio, M. Mayberg, and D. Janigro Loss of flow induces leukocyte-mediated MMP/TIMP imbalance in dynamic in vitro blood-brain barrier model: role of pro-inflammatory cytokines Am J Physiol Cell Physiol, October 1, 2006; 291(4): C740 - C749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sook Kim-Han, S. J. Kopp, L. L. Dugan, and M. N. Diringer Perihematomal Mitochondrial Dysfunction After Intracerebral Hemorrhage Stroke, October 1, 2006; 37(10): 2457 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Lee, B. J. Kim, and J.-K. Roh Silent microbleeds are associated with volume of primary intracerebral hemorrhage Neurology, February 14, 2006; 66(3): 430 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Juvela and C. S. Kase Advances in Intracerebral Hemorrhage Management Stroke, February 1, 2006; 37(2): 301 - 304. [Full Text] [PDF]
|
|
|
|
|
|
J. Wang and S. E. Tsirka Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage Brain, July 1, 2005; 128(7): 1622 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hanley and W. Hacke Critical Care and Emergency Medicine Neurology in Stroke Stroke, February 1, 2005; 36(2): 205 - 207. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Young and G.-Y. Yang Are There Genetic Influences on Sporadic Brain Arteriovenous Malformations? Stroke, November 1, 2004; 35(11_suppl_1): 2740 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Tayebjee, G. Y.H. Lip, and R. J. MacFadyen The Unifying Role of Matrix Metalloproteinases in Atheroma and Vascular Stroke Stroke, October 1, 2004; 35(10): 2239 - 2239. [Full Text] [PDF]
|
|